Nephrol Dial Transplant (2002) 17: 1802-1807
© 2002 European Renal Association-European Dialysis and Transplant Association
A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters
Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia
Background. Central venous catheters are frequently needed for the provision of haemodialysis, but their clinical usefulness is severely limited by infectious complications. The risk of such infections can be reduced by topical application of mupirocin to the exit sites of non-cuffed catheters or by the use of tunnelled, cuffed catheters. Whether mupirocin offers any additional protection against infection in patients with tunnelled, cuffed haemodialysis catheters has not been studied.
Methods. An open-label, randomized controlled trial was performed comparing the effect of thrice-weekly exit site application of mupirocin (mupirocin group) vs no ointment (control group) on infection rates and catheter survival in patients receiving haemodialysis via a newly inserted, tunnelled, cuffed central venous catheter. All patients were followed until catheter removal and were monitored for the development of exit site infections and catheter-associated bacteraemias.
Results. Fifty patients were enrolled in the study. Both the mupirocin (n=27) and control (n=23) groups were similar at baseline with respect to demographic characteristics, comorbid illnesses and causes of renal failure. Compared with controls, mupirocin-treated patients experienced significantly fewer catheter-related bacteraemias (7 vs 35%, P<0.01) and a longer time to first bacteraemia (log rank score 8.68, P<0.01). The beneficial effect of mupirocin was entirely attributable to a reduction in staphylococcal infection (log rank 10.69, P=0.001) and was still observed when only patients without prior nasal Staphylococcus aureus carriage were included in the analysis (log rank score 6.33, P=0.01). Median catheter survival was also significantly longer in the mupirocin group (108 vs 31 days, log rank score 5.9, P<0.05). Mupirocin use was not associated with any adverse patient effects or the induction of antimicrobial resistance.
Conclusions. Thrice-weekly application of mupirocin to tunnelled, cuffed haemodialysis catheter exit sites is associated with a marked reduction in line-related sepsis and a prolongation of catheter survival.
Keywords: antibiotics therapeutic use; bacteraemia; catheterization, central venous; dialysis; equipment contamination; staphylococcal infections
Correspondence and offprint requests to: Associate Professor David W. Johnson, Department of Renal Medicine, Level 2, Ambulatory Renal and Transplant Services Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane Qld 4102, Australia. Email: david_johnson{at}health.qld.gov.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. S. Rabindranath, T. Bansal, J. Adams, R. Das, R. Shail, A. M. MacLeod, C. Moore, and A. Besarab Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3763 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Vandecasteele, J. R. Boelaert, and A. S. De Vriese Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1388 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steczko, S. R. Ash, D. E. Nivens, L. Brewer, and R. K. Winger Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens) Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Winnett, J. Nolan, M. Miller, and N. Ashman Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3592 - 3598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Labriola, R. Crott, and M. Jadoul Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1666 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. James, J. Conley, M. Tonelli, B. J. Manns, J. MacRae, B. R. Hemmelgarn, and for the Alberta Kidney Disease Network Meta-analysis: Antibiotics for Prophylaxis against Hemodialysis Catheter-Related Infections Ann Intern Med, April 15, 2008; 148(8): 596 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Allon Current Management of Vascular Access Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 786 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Johnson, C. van Eps, D. W. Mudge, K. J. Wiggins, K. Armstrong, C. M. Hawley, S. B. Campbell, N. M. Isbel, G. R. Nimmo, and H. Gibbs Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1456 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Foley, H. Guo, J. J. Snyder, D. T. Gilbertson, and A. J. Collins Septicemia in the United States Dialysis Population, 1991 to 1999 J. Am. Soc. Nephrol., April 1, 2004; 15(4): 1038 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F.L. Wertheim, M. C. Vos, A. Ott, A. Voss, J. A.J.W. Kluytmans, C. M.J.E. Vandenbroucke-Grauls, M. H.M. Meester, P. H.J. van Keulen, and H. A. Verbrugh Mupirocin Prophylaxis against Nosocomial Staphylococcus aureus Infections in Nonsurgical Patients: A Randomized Study Ann Intern Med, March 16, 2004; 140(6): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ponikvar Blood purification in the intensive care unit Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v63 - 67. [Abstract] [Full Text] [PDF]
|
|